Clinical Study

A Phase III Double-Blind Trial For Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo For Patients With Tumors Harboring The Anaplastic Lymphoma Kinase (Alk) Fusion Protein

Posted Date: Feb 16, 2017

  • Investigator: John Morris
  • Co-Investigator: Sarah Elizabeth Figueira
  • Specialties: Thoracic Surgery, Hematology/Oncology, Oncology, Cancer, Lung Cancer, Radiation Oncology
  • Type of Study: Drug

The purpose of this research is to compare any good and bad effects of using the study drug, crizotinib after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. The addition o


To Be Eligible To Participate, Patients Must Have Alk-Positive Non-Small Cell Lung Cancer Which Has Been Removed By A Surgeon.


Early Stage, Nsclc, Cancer, Non-Small Cell Lung Cancer, E4512

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.